- Quotes
- Dashboard
- Chart
- Historical Prices
- Options
- News & PR
- News
- Market Currents
- Press Releases
- Coverage
- Cramer
- Top Analysts
- Business Intelligence
- Transcripts
- Events
- Key Developments
- Earnings
- History & Projected
- Consensus
- Peer Earnings
- Filings
- SEC Filings
- Annual Report
- Financials
- Income Statement
- Balance Sheet
- Cash Flow
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
INHX Market Currents
more »
-
January 27 Idenix Pharmaceuticals (IDIX) -9.6% after Stifel Nicolaus downgrades shares to Sell from Hold at Stifel Nicolaus, which believes the "significant difference" in potency existing between IDIX's hepatitis C drug and those made by Pharmasset (VRUS) and Inhibitex (INHX) has important implications on how remaining "potential consolidators" strategically view the companies.
Comment![Healthcare, On the Move]
INHX in Focus
more »
INHX Related Articles
more »
INHX News
more »
-
at MarketWatch.com (Feb 1, 2012)
-
at CNBC.com (Jan 9, 2012)
-
at CNBC.com (Jan 9, 2012)
-
at MarketWatch.com (Jan 9, 2012)
-
at CNBC.com (Jan 9, 2012)
INHX Press Releases and Filings
more »
Currently, there are no press releases or filings on INHX.
INHX Latest Transcript
more »
Currently, there are no transcripts for INHX.
INHX Cramer
more »
Currently, there are no Cramer articles on INHX.
INHX Instablog posts
more »
INHX vs. ETF Alternatives
Company Description
Currently, there's no company description for INHX.